Registry of long-term antithrombotic therapy for atrial fibrillation
Official title: Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Atrial Fibrillation
Run by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · NCT04347187 · Data updated 2026-11-12
This study looks at how safe and effective long-term blood-thinning treatments are for people with atrial fibrillation by tracking any complications they might have.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation Government |
| Locations | 1 site (Moscow) |
| Status | Recruiting |
| Started | January 15, 2015 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT04347187 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with documented atrial fibrillation and a CHA2DS2VASC score greater than 1.
✕Probably not a fit
Patients who are unwilling or unable to provide informed consent or have severe comorbid conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the rates of ischemic and hemorrhagic complications associated with long-term antithrombotic therapy in patients diagnosed with atrial fibrillation. Conducted at a single center in Russia, the study will involve patients who meet specific criteria for antithrombotic treatment. By documenting outcomes over time, the study seeks to provide insights into the safety and efficacy of anticoagulants in this patient population.
Why it matters
Potential benefit: If successful, this study could enhance understanding of the risks associated with long-term antithrombotic therapy, potentially leading to improved treatment strategies for patients with atrial fibrillation.
How similar studies have gone: Other studies have explored antithrombotic therapy in atrial fibrillation, indicating that this approach has been previously tested, though the specific focus on long-term outcomes in this registry may provide novel insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Documented atrial fibrillation with CHA2DS2VASC \> 1 Exclusion Criteria: * Subjects who are unwilling or unable to provide informed consent. ACS within 12 months before inclusion Severe CHF (NYHA IV) Stroke within 6 months before inclusion Severe liver or muscle disease Severe kidney disease / renal failure with creatinine \> 3 mg/dl Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention
Where it's running
-
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Moscow, Russia Recruiting
Study contacts
- Principal investigator: Elizaveta Panchenko, PhD — National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Study coordinator: Ekaterina Kropacheva, PhD
- Email: katekrab@list.ru
- Phone: +79166760695
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.
-
Dual Energy ablation with SmartTouch SF catheter in persistent atrial fibrillation
This study tests a pulsed field and radiofrequency ablation system to treat persistent atrial fibrillation in adults who have not responded well to prior medications.
-
Identifying AF patients who may need more than standard ablation using Volta AF-Xplorer II
This trial tests whether AI-identified dispersion areas during AF ablation can predict recurrence after a standard pulmonary vein isolation in patients with persistent AF.
-
4D intracardiac echocardiography to guide left atrial appendage occlusion procedures
A new 4D ICE catheter is being tested alongside standard imaging to see if it can safely guide left atrial appendage occlusion procedures for adults with atrial fibrillation.
-
Thoracoscopic vs Catheter Ablation as the First Rhythm Control in Atrial Fibrillation with a Large Left Atrium
This trial tests whether thoracoscopic surgical ablation is better at keeping atrial fibrillation under control than catheter ablation in people with persistent AF and a large left atrium who have not had an ablation before.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.